Zobrazeno 1 - 10
of 53
pro vyhledávání: '"J Harvey Turner"'
Autor:
Murali Kesavan, Danielle Meyrick, Marat Gallyamov, J. Harvey Turner, Sharon Yeo, Giuseppe Cardaci, Nat P. Lenzo
Publikováno v:
Diagnostics, Vol 11, Iss 3, p 515 (2021)
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a significant contributor to the global cancer burden. lutetium-177-prostate-specific membrane antigen radioligand therapy (177Lu-PSMA RLT) is an effective salvage treatment.
Externí odkaz:
https://doaj.org/article/0ba78a99ed934bc7923b5dcbd518f731
Autor:
J Harvey Turner
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::137f916e9829c7733fa918bee6817dfa
https://doi.org/10.1089/cbr.2023.0009
https://doi.org/10.1089/cbr.2023.0009
Autor:
J. Harvey Turner
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 36:711-719
What, precisely, are we seeking to achieve in offering 'life-saving' treatment to patients with cancer? Research funding agencies and pharmaceutical industry media releases, and government cancer screening programs all promise that their cancer progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ada84befe5b03f114344fbb750be0b69
https://doi.org/10.1089/cbr.2021.0355
https://doi.org/10.1089/cbr.2021.0355
Autor:
J. Harvey Turner
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 36:617-623
The landscape of nuclear oncology is rapidly changing. The advent of molecular radionuclide theranostics, multidisciplinary tumor board decision making, artificial intelligence and radiomics interpretation of diagnostic imaging, evolution of pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afff1ebf59c13929bb1b4866feb7ce80
https://doi.org/10.1089/cbr.2021.0152
https://doi.org/10.1089/cbr.2021.0152
Autor:
Ghassan Zammar, Andrew D McQuillan, James T McQuillan, William Macdonald, Murali Kesavan, J. Harvey Turner
Publikováno v:
British Journal of Haematology. 196:237-241
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79201b078d14d8f217d09476ddc1f892
https://doi.org/10.1111/bjh.17758
https://doi.org/10.1111/bjh.17758
Publikováno v:
Endocrine-Related Cancer. 28:521-527
Thirty-seven patients with advanced gastroenteropancreatic neuroendocrine tumors (GEPNETs) were treated on a prospective phase II single-center study with four cycles of 7.8 GBq 177Lu-octreotate combined with capecitabine and temozolomide chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7b571a54ac9516ff36837b9697d3144
https://doi.org/10.1530/erc-21-0082
https://doi.org/10.1530/erc-21-0082
Autor:
J. Harvey Turner
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 36:1-9
Pharmaceutical industry clinical trials are ethically problematic: human research subjects are being used as a means to the end of demonstrating statistically significant efficacy of novel anticancer agents to achieve regulatory registration and mark
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f63ce129643693ab9a00ba9324cfce17
https://doi.org/10.1089/cbr.2020.4129
https://doi.org/10.1089/cbr.2020.4129
Publikováno v:
Diagnostics, Vol 8, Iss 1, p 16 (2018)
Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by 68Ga-PSMA-positron emission tomography/computed tomography (68Ga-PSMA-PET/CT) imaging. This novel mo
Externí odkaz:
https://doaj.org/article/b53e71638a36455a9b65d29b5c841d4c
Autor:
Murali Kesavan, J. Harvey Turner
Publikováno v:
Cancer biotherapyradiopharmaceuticals. 37(3)
Emergent genomic analytic techniques in patients with cancer offer the potential to define the risk of myelo dysplastic syndrome (MDS) and acute leukemia (AL) manifesting following targeted radionuclide therapy of metastatic lymphoma, neuroendocrine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5573db8093d04d41344a50d57b18d3ff
https://pubmed.ncbi.nlm.nih.gov/34871036
https://pubmed.ncbi.nlm.nih.gov/34871036
Autor:
Sharon Yeo, Murali Kesavan, Marat O. Gallyamov, J. Harvey Turner, Nat Lenzo, Danielle Meyrick, Giuseppe Cardaci
Publikováno v:
Diagnostics, Vol 11, Iss 515, p 515 (2021)
Diagnostics
Diagnostics
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a significant contributor to the global cancer burden. lutetium-177-prostate-specific membrane antigen radioligand therapy (177Lu-PSMA RLT) is an effective salvage treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4812d2fb20f6989ed5353eadc9f2b41
https://www.mdpi.com/2075-4418/11/3/515
https://www.mdpi.com/2075-4418/11/3/515